Astellas, Sony partner up for antibody-drug conjugate platform to create 'better performing' drugs
Astellas and Sony Corporation have teamed up to develop a new antibody-drug conjugate platform that delivers drugs to the target cells in a bid to develop “better performing” ADCs, Astellas announced Tuesday.
The two companies have been in talks to develop the platform since July 2022, and have already done feasibility studies using human cancer cells. In the project, the companies will use Sony’s polymeric material, called Kiravia Backbone, as the “linker” between ADCs and the target cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.